Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin; Edwin DeJesus; Paul E Sax; Jose R Arribas; Samir K Gupta; Claudia Martorell; Jeffrey L Stephens; Hans-Jurgen Stellbrink; David Wohl; Franco Maggiolo; Melanie A Thompson; Daniel Podzamczer; Debbie Hagins; Jason A Flamm; Cynthia Brinson; Amanda Clarke; Hailin Huang; Rima Acosta; Diana M Brainard; Sean E Collins; Hal Martin

doi:10.1016/s2352-3018(20)30099-0

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

The Lancet HIV ◽

10.1016/s2352-3018(20)30099-0 ◽

2020 ◽

Vol 7 (6) ◽

pp. e389-e400 ◽

Cited By ~ 1

Author(s):

Chloe Orkin ◽

Edwin DeJesus ◽

Paul E Sax ◽

Jose R Arribas ◽

Samir K Gupta ◽

...

Keyword(s):

Initial Treatment ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Dose Combination ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32340-1 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2073-2082 ◽

Cited By ~ 97

Author(s):

Paul E Sax ◽

Anton Pozniak ◽

M Luisa Montes ◽

Ellen Koenig ◽

Edwin DeJesus ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30077-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e355-e363 ◽

Cited By ~ 27

Author(s):

David A Wohl ◽

Yazdan Yazdanpanah ◽

Axel Baumgarten ◽

Amanda Clarke ◽

Melanie A Thompson ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32299-7 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2063-2072 ◽

Cited By ~ 107

Author(s):

Joel Gallant ◽

Adriano Lazzarin ◽

Anthony Mills ◽

Chloe Orkin ◽

Daniel Podzamczer ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Randomised Controlled ◽

Hiv 1

Download Full-text

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30080-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e364-e372 ◽

Cited By ~ 28

Author(s):

Hans-Jürgen Stellbrink ◽

José R Arribas ◽

Jeffrey L Stephens ◽

Helmut Albrecht ◽

Paul E Sax ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

10.26226/morressier.5aeaf2d35800a00019097f85 ◽

2018 ◽

Author(s):

Christian Wisskirchen ◽

Hans-Jürgen Stellbrink

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination ◽

Hiv 1

Download Full-text

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Case Medical Research ◽

10.31525/ct1-nct04132674 ◽

2019 ◽

Author(s):

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Marginalized Populations ◽

Dose Combination ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fixed-Dose Combination for Treatment of HIV in Adolescents and Children: Week 48 Results from an Open-Label, Multicentre, Phase 2/3 Paediatric Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3666840 ◽

2020 ◽

Author(s):

Aditya H. Gaur ◽

Mark F. Cotton ◽

Carina A. Rodriguez ◽

Eric J. McGrath ◽

Elizabeth Hellstrom ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Paediatric Trial ◽

Dose Combination ◽

Tenofovir Alafenamide

Download Full-text

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(18)30092-4 ◽

2018 ◽

Vol 5 (7) ◽

pp. e357-e365 ◽

Cited By ~ 35

Author(s):

Jean-Michel Molina ◽

Douglas Ward ◽

Indira Brar ◽

Anthony Mills ◽

Hans-Jürgen Stellbrink ◽

...

Keyword(s):

Fixed Dose ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13491 ◽

2018 ◽

Vol 21 (1) ◽

pp. 103-111 ◽

Cited By ~ 1

Author(s):

Ji Cheol Bae ◽

Kyung Wan Min ◽

Yong Hyun Kim ◽

Kyoung-Ah Kim ◽

Eun-Gyoung Hong ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Dose Combination

Download Full-text

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial

The Lancet Child & Adolescent Health ◽

10.1016/s2352-4642(21)00165-6 ◽

2021 ◽

Author(s):

Aditya H Gaur ◽

Mark F Cotton ◽

Carina A Rodriguez ◽

Eric J McGrath ◽

Elizabeth Helström ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Dose Combination ◽

Tenofovir Alafenamide

Download Full-text